Why the study?
Does pimagedine prevent the progression of overt nephropathy in patients with type 1 diabetes?
Does pimagedine prevent the progression of overt nephropathy in patients with type 1 diabetes?
Although it did not reach statistical significance for its primary endpoint, the study provides the first clinical proof of concept that inhibiting advanced glycation end product formation can attenuate serious complications of type 1 diabetes.
Pimagedine does not significantly slow overt nephropathy progression in type 1 diabetes; leaves open whether AGE inhibition confers clinical benefit.
While this study did not demonstrate a statistically significant beneficial effect of pimagedine on the progression of overt nephropathy resulting from type 1 diabetes, it is noteworthy in providing the first clinical proof of the concept that inhibiting advanced glycation end product formation can result in a clinically important attenuation of the serious complications of type 1 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Bolton et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: